Integrity Laboratories, LLC

Integrity Laboratories, LLC was paid $4.14M by Medicaid between Jan 2018 and Dec 2024, across 56 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 31% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Tennessee

Rank by total paid#17 of 70

Median peer was paid$141K

This provider vs. median29×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	48,193	$1.25M
2019	20,205	$794K
2020	27,387	$795K
2021	30,684	$750K
2022	13,013	$361K
2023	5,951	$45K
2024incomplete	8,633	$141K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	31%	39,027	22,155	$1.28M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	27%	18,031	12,165	$1.10M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	14%	26,642	16,411	$568K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	12%	9,354	6,243	$481K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	6.3%	18,490	13,353	$261K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	3.7%	2,555	1,938	$154K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.4%	934	662	$58K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.3%	2,061	1,400	$54K
87799		<1%	995	656	$19K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	363	279	$13K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	144	112	$12K
80171		<1%	1,772	1,207	$12K

44 more codes

87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	837	$11K
80184		<1%	1,660	$10K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	835	$10K
87999		<1%	576	$9K
87582		<1%	318	$8K
87634		<1%	733	$7K
87640		<1%	1,353	$7K
87653		<1%	1,031	$6K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	277	$6K
87631		<1%	402	$5K
81025		<1%	2,367	$5K
84311		<1%	6,446	$4K
82570		<1%	6,401	$4K
87481		<1%	192	$4K
83986		<1%	6,451	$4K
87641		<1%	452	$3K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	155	$3K
87500		<1%	412	$3K
81514		<1%	60	$2K
87498		<1%	454	$2K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	179	$1K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	172	$1K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	168	$1K
80074		<1%	37	$965.59
87541		<1%	49	$897.46
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	50	$852.98
87632		<1%	481	$850.43
87800		<1%	121	$827.64
87486		<1%	43	$800.74
87511		<1%	66	$758.15
84443	Thyroid stimulating hormone (TSH)	<1%	73	$722.35
80061	Lipid panel	<1%	77	$555.22
87487		<1%	176	$506.53
87482		<1%	114	$503.11
80053	Comprehensive metabolic panel	<1%	92	$497.55
87542		<1%	176	$493.68
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	22	$344.83
87592		<1%	35	$283.92
87563		<1%	40	$264.45
87530		<1%	13	$200.90
87492		<1%	35	$196.80
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	37	$183.93
87797		<1%	18	$119.56
87512		<1%	12	$99.20

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCLEVENGER, CHRISTIAN (OWNER)